

論文(2013 年以降)

1. Nakashima H, Henmi T, Minami K, Uchida Y, Shiraishi Y, Nunohiro T, Maemura K: Obstructive sleep apnoea increases the incidence of morning peak of onset in acute myocardial infarction. *Eur Heart J Acute Cardiovasc Care*. 2(2): 153-8, 2013.
2. Nakashima H, Umeyama Y, Minami K: Successive immunosuppressive treatment of fulminant myocarditis that is refractory to mechanical circulatory support. *Am J Case Rep*. 23: 116-119, 2013.
3. Kario K, Ando S, Kido H, Nariyama J, Takiuchi S, Yagi T, Shimizu T, Eguchi K, Ohno M, Kinoshita O, Yamada T, APPENDIX Nunohiro T. The effects of the L/N-type calcium channel blocker (cilnidipine) on sympathetic hyperactive morning hypertension: results from ACHIEVE-ONE. *Journal of Clinical Hypertension* 2013 Feb; 15(2): 133-42.
4. White WB, Cannon CP, Heller SR; EXAMINE Investigators, Collaborators Nunohiro T. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. *N Engl J Med*. 2013 Oct 3; 369(14): 1327-35.
5. Hokusai-VTE Investigators, Büller HR, Décousus H, Wells P, Collaborators Nunohiro T. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. *N Engl J Med*. 2013 Oct 10; 369(15): 1406-15.
6. Uchida Y, Nakashima H, Takeshita S: Modified mother-child technique using a buddy wire. *J Invasive Cardiol*. 26(5): E52-3, 2014.
7. Pieske B, Butler J, Gheorghiade M; SOCRATES Investigators and Coordinators, Collaborators Nunohiro T. Rationale and design of the SOLuble guanylate Cyclase stimulator in heart failure Studies (SOCRATES). *Eur J Heart Fail*. 2014 Sep; 16(9): 1026-38.
8. Nakashima H, Kurobe M, Minami K, Furudono S, Uchida Y, Amenomori K, Nunohiro T, Takeshita S, Maemura K: Effects of moderate-to-severe obstructive sleep apnea on the clinical manifestations of plaque vulnerability and the progression of coronary atherosclerosis in patients with acute coronary syndrome. *Eur Heart J Acute Cardiovasc Care*. 4(1):75-84, 2015.
9. Bentley-Lewis R, Aguilar D, McMurray JJ, Ping L, Probstfield JL, Solomon SD, Tardif JC, Wu Y, Pfeffer MA; ELIXA Investigators, Collaborators Nunohiro T. Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. *Am Heart J*. 2015 May; 169(5): 631-638.e7.
10. Gheorghiade M, Greene SJ, Butler J, Filippatos G, Lam CS, Maggioni AP, Ponikowski P, Shah SJ, Solomon SD, Kraigher-Krainer E, Samano ET, Müller K, Roessig L, Pieske B; SOCRATES-REDUCED Investigators and Coordinators, Collaborators Nakashima H, Nunohiro T, Furudono S. Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic

Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. *JAMA*. 2015 Dec 1; 314(21): 2251-62.

11. Pfeffer MA, Claggett B, Tardif JC; ELIXA Investigators, Collaborators Nunohiro T. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. *N Engl J Med*. 2015 Dec 3; 373(23): 2247-57.
12. Nakashima H, Mashimo Y, Kurobe M, Muto S, Furudono S, Maemura K: Impact of Morning Onset on the Incidence of Recurrent Acute Coronary Syndrome and Progression of Coronary Atherosclerosis in Acute Myocardial Infarction. *Circ J*. 81(3): 361-367, 2017.
13. Sabatine MS, Giugliano RP, Pedersen TR; FOURIER Steering Committee and Investigators, Collaborators Nunohiro T. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. *N Engl J Med*. 2017 May 4; 376(18): 1713-1722.
14. Asakura M, Nunohiro T, Kitakaze M: Does Treatment of Impaired Glucose Tolerance Improve Cardiovascular Outcomes in Patients with Previous Myocardial Infarction? *Cardiovasc Drugs Ther*. 2017 Aug; 31(4): 401-411.
15. Zannad F, Anker SD, Byra WM; COMMANDER HF Investigators, Collaborators Nunohiro T. Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease. *N Engl J Med*. 2018 Oct 4; 379(14): 1332-1342.
16. McMurray JJV, Solomon SD, Inzucchi SE, Appendix Nunohiro T. Dapagliflozin in patients with Heart Failure and Reduced Ejection Fraction. *N Engl J Med*. 2019 Nov 21; 381: 1995-2008.
17. Armstrong PW, Pieske B, O'Connor CM; VICTORIA Study Group. Collaborators Nunohiro T. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. *N Engl J Med*. 2020 May 14;382(20):1883-1893.
18. Okumura K, Akao M, Yamashita T; ELDERCARE- AF Committees and Investigators. Collaborators Nunohiro T. Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation. *N Engl J Med*. 2020 Oct 29;383(18):1735-1745
19. Docherty KF, Jhund PS, McMurray JJV; DAPA-HF Investigators and Committees. Collaborators Nunohiro T. Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy. *Diabetes Care*. 2020 Nov;43(11):2878-2881.
20. Lam CSP, Giczevska A, Sliwa K; VICTORIA Study Group. Collaborators Nunohiro T. Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial. *VICTORIA Study Group. Collaborators Nunohiro T. JAMA Cardiol*. 2021 Jun 1;6(6):706-712.
21. Docherty KF, Jhund PS, McMurray JJV; DAPA-HF Investigators and Committees. Collaborators Nunohiro T. Extrapolating Long-term Event-Free and Overall Survival With

- Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial. JAMA Cardiol. 2021 Jul 28. Online ahead of print
22. PCI 時代の急性心筋梗塞患者の来院時血糖値と長期予後の関連布廣龍也、黒部昌也、中嶋寛 心臓 第 48 号 第 1 号(2016.1.15)
 23. 房室ブロックの心電図を読む 布廣龍也 Heart View Vol.20 No.4: 90-96, 2016
 24. 急性心筋梗塞を発症した 2 型糖尿病患者での冠動脈プラーク特性 – 光干渉断層法 (OCT) を用いて – 布廣龍也、古殿真之介、中嶋寛 循環器内科, 81(2): 207-212, 2017
 25. 1000 枚見て覚える心電図ギャラリー(電子書籍)分担執筆 布廣龍也 日本医事新報社 (2018)
 26. 215 症例みて覚える心電図ギャラリー(電子書籍)分担執筆 布廣龍也 日本医事新報社 (2019.1.31)
 27. みて覚える心電図ギャラリー 第 19 回布廣龍也 週刊日本医事新報 No.4982 (2019.10.19)
 28. 福嶋理知 末永英隆 布廣龍也 前村浩二 右心室ペーシング誘発性心筋症による心不全に対する His 束ペーシングの 1 例 心臓 2020 5 : 52 : 503-509
 29. 奈良谷俊 木下和久 布廣龍也 栗山一孝 担癌状態による凝固能亢進が原因と考えられた深部静脈血栓症の 1 症例 医学検査 2021 1 : 70 : 138-143
 30. みて覚える心電図ギャラリー 第 68 回 布廣龍也 週刊日本医事新報 No.5059 (2021. 4.10)
 31. 急性心筋梗塞患者の高 TG 血症と small dense LDL への影響 布廣龍也 Progress in medicine. 41 : 665-671,2021 7.
 32. Liver stiffness assessed by Fibrosis-4 index predicts heart failure in AMI patients T Nunohiro, K Furukawa, S Kuwasaki, S Kusumoto, S Furudono, M Takeno
European Heart Journal, Volume 43, Issue Supplement 1, February 2022, ehab849.07804
 33. みて覚える心電図ギャラリー 第 111 回 布廣龍也 週刊日本医事新報 No.5103 (2022.2.12)
 34. Circ J : 88(11):1825-1832. Epub 2024 Sep 14. Impact of Implementation of a Region-Wide Low-Density Lipoprotein Cholesterol Management Clinical Pathway for the Secondary Prevention of Acute Myocardial Infarction. Masaya Kurobe, Kensho Baba, Tatsuya Nunohiro
 35. Side Branch Occlusion After Intravascular Lithotripsy. A Case Report.
Setoguchi A, Takeno M, Kusumoto S, Nunohiro T et al. Cureus 17(8) August 12, 2025
 36. Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials. Zannad F, O'Connor CM, et al; VICTORIA and VICTOR Study Groups T.Nunohiro. Lancet. 2025 Sep 27;406(10510):1351-1362.
 37. Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension.
Flack JM, Azizi M, Brown JM, et al; BaxHTN Investigators T.Nunohiro. N Engl J Med. 2025 Oct 9;393(14):1363-1374.